Patel Chirag K. 4

4 · Amneal Pharmaceuticals, Inc. · Filed Mar 3, 2026

Form 4

Period: 2026-03-02

DirectorPresident & Co-CEO

Transactions

Award
Restricted Stock Units
[F1][F2]
2026-03-02+190,632→ 190,632 total
→ Class A Common Stock (190,632 underlying)
Award
Performance-Based Restricted Stock Units
[F3][F4]
2026-03-02+354,031→ 354,031 total
→ Class A Common Stock (354,031 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
[F2]The restricted stock units vest in four equal annual installments beginning on March 2, 2027.
[F3]Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
[F4]Represents a performance-based restricted stock unit grant of 354,031 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Signature

/s/ Denis Butkovic, Attorney-in-Fact|2026-03-03

Documents

1 file